URGN Investors Have the Opportunity to Lead the UroGen Securities Fraud Lawsuit with Faruqi & Faruqi, LLP
Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In UroGen To Contact Him Directly To Discuss Their Options
If you suffered losses exceeding $75,000 in UroGen between July 27, 2023 and May 15, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
[You may also click here for additional information]
New York, New York--(Newsfile Corp. - June 3, 2025) - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against UroGen Pharma Ltd. ('UroGen' or the 'Company') (NASDAQ: URGN) and reminds investors of the July 28, 2025 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
[ This image cannot be displayed. Please visit the source: https://images.newsfilecorp.com/files/6455/254224_c886127d94b12b7f_001full.jpg ]
Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia. The firm has recovered hundreds of millions of dollars for investors since its founding in 1995. See www.faruqilaw.com.
As detailed below, the complaint alleges that the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) the ENVISION clinical study was not designed to demonstrate substantial evidence of effectiveness of UGN-102 because it lacked a concurrent control arm; (2) as a result, the Company would have difficulty demonstrating that the duration of response endpoint was attributable to UGN-102; (3) UroGen failed to heed the FDA's warnings about the study design used to support a drug application for UGN-102; (4) as a result of the foregoing, there was a substantial risk that the NDA for UGN-102 would not be approved; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
On May 16, 2025, before the market opened, the U.S. Food and Drug Administration ('FDA') published a briefing document in advance of its Oncologic Drugs Advisory Committee meeting regarding UroGen's new drug application ('NDA') for UGN-102, which stated the agency doubted whether the submitted data was sufficient to conclude that UGN-102 was effective. In the briefing document, the FDA stated: "[g]iven that [the ENVISION trial] lacked a concurrent control arm, the primary endpoints of complete response (CR) and duration of response (DOR) are difficult to interpret.' The FDA also said it had 'recommended a randomized trial design to the Applicant several times during their product's development due to concerns with interpreting efficacy results' but UroGen 'chose not to conduct a randomized trial with a design and endpoints that the FDA considered appropriate.'
On this news, UroGen's stock price fell $2.54, or 25.8%, to close at $7.31 per share on May 16, 2025, on unusually heavy trading volume.
Then, on May 21, 2025, before the market opened, the Oncologic Drugs Advisory Committee voted against approving the UGN-102 NDA. The committee found that the overall benefit-risk of the investigational therapy UGN-102 (intravesical mitomycin) is not favorable in patients with recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer.
On this news, UroGen's stock price fell $3.37, or 44.7%, to close at $4.17 per share on May 21, 2025, on unusually heavy trading volume.
The court-appointed lead plaintiff is the investor with the largest financial interest in the relief sought by the class who is adequate and typical of class members who directs and oversees the litigation on behalf of the putative class. Any member of the putative class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Your ability to share in any recovery is not affected by the decision to serve as a lead plaintiff or not.
Faruqi & Faruqi, LLP also encourages anyone with information regarding UroGen's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
To learn more about the UroGen Pharma Ltd. class action, go to www.faruqilaw.com/URGN or call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).
Follow us for updates on LinkedIn, on X, or on Facebook.
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/254224
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Bloomberg
33 minutes ago
- Bloomberg
Long-Dated Bonds Are Tough Sell to Investors These Days
Governments selling long-dated bonds might just have to get used to a lukewarm reception from investors. Weak demand for a slew of auctions of 20-, 30- or 40-year bonds — among the longest maturities that countries tend to sell — has triggered a fresh round of soul-searching over the depth of demand for this type of asset. The yield on a Bloomberg global gauge of longer-dated sovereign yields has climbed to around the highest since 2008, another sign of tepid appetite.
New York Times
34 minutes ago
- New York Times
Edmonton avoids a painful repeat, and Texas stuns Texas Tech late
The Pulse Newsletter 📣 | This is The Athletic's daily sports newsletter. Sign up here to receive The Pulse directly in your inbox. Good morning! Refuse that intentional walk today. We can quibble with quantitative analyses and details later. But watching Game 1 of both the Stanley Cup Final and the Women's College World Series championship last night left me with the best eye test result you can hope for in these situations: It feels like the two best teams are playing each other at the end. Advertisement Truly a wonderful thing. No flukes. Best-on-best, and last night's winners were decided on singular moments: We must start with a scintillating hockey game in Edmonton, where the Oilers — losers of last year's Stanley Cup Final against this same Panthers team — took a 1-0 series lead with a 4-3 overtime win. Florida was up 3-1 early in the second in this one, too. Here's the game winner from Leon Draisaitl with just 31 seconds left in the overtime period: LEON DRAISAITL IS EDMONTON'S HERO 🔥 The Oilers rally back from a 3-1 deficit to take Game 1 in OT! 🎥 @Sportsnet — The Athletic (@TheAthletic) June 5, 2025 Avoid a 3-0 deficit this year? ✅ On the diamond, we saw an intentional walk gone awry win the game for Texas. It was wild. Texas Tech, fueled by star pitcher NiJaree Canady, had a 1-0 lead in the sixth inning when the Red Raiders decided to give Reese Atwood a free bag with two runners on base. The problem was that Atwood refused the offer: After review, this pitch was obstructed by @atwood_reese bat. #HookEm | 📺: ESPN — Texas Softball (@TexasSoftball) June 5, 2025 That was essentially the game. Longhorns up 1-0 in the series. Let's keep moving: Just a few weeks ago, Loïs Boisson was mostly known for a deodorant incident. Boisson, the 22-year-old French tennis revelation, began this year's French Open ranked No. 361 in the world. She had been aching for this opportunity to play in front of French fans, one year after a brutal injury forced her to forgo a wild-card spot in the tournament. This morning, Boisson is a phenomenon. The last remaining French player in the tournament, facing world No. 2 Coco Gauff for a spot in the final. A quick introduction: Victory is a great cologne, and Boisson is much more than the victim of some petty routine. Today's match against Gauff is a must-watch. More on that later, but I recommend listening to 'The Tennis Podcast' on Boisson before she takes the court. Catch that here. Former IU players file sexual assault suit More than a dozen former Indiana men's basketball players have accused former team physician Dr. Bradford Bomba of sexual assault during his decades of work at the school. Two former Hoosiers, Haris Mujezinovic and Charlie Miller, filed suit in October against the university and head trainer Tim Garl, alleging both had knowledge of Bomba's actions and the school 'acted with deliberate indifference' toward his behavior. Two other players joined the suit in April, and yesterday an attorney told The Athletic at least 10 more players plan to come forward. Bomba died in May, and some players have said legendary Hoosiers coach Bob Knight was aware of Bomba's alleged impropriety. More details in our full report. Advertisement Manfred regrets ESPN opt-out The messy breakup between MLB and ESPN has moved past the anger stage and into nostalgia, as commissioner Rob Manfred said yesterday he regrets the move. Sources told The Athletic's Evan Drellich and Andrew Marchand that the league is in negotiations with multiple networks over the rights ESPN once had, and the packages are nowhere near the value of ESPN's offering. Manfred hopes to have a rights deal finalized soon. See his full comments. More news 📫 Love The Pulse? Check out our other newsletters. 📺 French Open: Women's Semifinals 9 a.m. ET on TNT/Max If you're able, throw this on this morning. First up is top-seeded Aryna Sabalenka against Iga Świątek for a spot in the final. Boisson-Coco Gauff follows. Both should be great. 📺 WCWS: Texas vs. Texas Tech, Game 2 8 p.m. ET on ESPN Texas can win its first title here. Easy call to watch. 📺 NBA: Pacers at Thunder 8:30 p.m. ET on ABC Finally, after nearly a week of waiting, the finals are here. We've talked about it plenty. I expect this game to be fast — Indiana's pace-driven offense against Oklahoma City's swarming defense that gorges on fast-break points. As Zach Harper said yesterday, the basketball itself will be good. Get tickets to games like these here. For all of the angles in this NBA Finals, I think it comes down to one guy: Tyrese Haliburton. Shakeia Taylor has a great story today on the league's new premier antagonist, a player who loves his haters. Former Seahawks wide receiver Doug Baldwin was against 'shrink dudes.' Then he worked with one. Max Muncy is mashing for the Dodgers again. His redemption arc is nearly complete. Fun story: Jeff Hoffman doesn't play for the Phillies anymore, but he'll always have a piece of Philly. No, literally. Most-clicked in the newsletter yesterday: Our story on the Steelers writing a letter to fans angry about players showing up to a Donald Trump rally. Read it here. Advertisement Most-read on the website yesterday: Andrew Marchand's column on how ESPN messed up its announcer trio for the NBA Finals. Ticketing links in this article are provided by partners of The Athletic. Restrictions may apply. The Athletic maintains full editorial independence. Partners have no control over or input into the reporting or editing process and do not review stories before publication.
New York Times
34 minutes ago
- New York Times
Thousands of Club World Cup tickets unsold, Brailsford steps back, Ronaldo's Portugal winner
The Athletic FC ⚽ is The Athletic's daily football (or soccer, if you prefer) newsletter. Sign up to receive it directly to your inbox. Hello! It's almost Club World Cup time. Don't all rush at once. ✂️ More CWC ticket price cuts 🚶 Brailsford steps aside at Man Utd 💰 £55m bid for Bryan Mbeumo 🏎️ Leeds Utd race Red Bull F1 The Athletic's Felipe Cardenas has an interview today with Mattias Grafstrom. I don't imagine the name will immediately ring a bell, but it's worth remembering. Grafstrom, a Swede, is FIFA's secretary general, with more than a little power. He was once chief of staff for its president, Gianni Infantino. Advertisement He's also the man who redesigned FIFA's Club World Cup (CWC), creating the 32-team tournament which starts in the United States next week. It was interesting to see him tell Felipe that the CWC was 'not a commercial venture as such'. From the outside looking in, it doesn't seem to be anything else. DAZN, for instance, paid $1billion for broadcast rights (which no other outlet wanted at that price — but let's not get bogged down in that). The 2025 winners will earn $125m, a Champions League-esque fee for considerably less effort. Grafstrom says FIFA is trying to grow the sport but, fundamentally, it's taken big money for some of the teams involved to give the competition their full attention. Unfortunately for FIFA, the paying public aren't rushing to buy into it. Adam Crafton reports that the opening match, between Inter Miami and Egyptian team Al Ahly in Miami on June 14, is struggling to sell out. The game, likely to feature Lionel Messi (above), is nowhere near capacity, so ticket prices are being cut. Is a late rush coming? Or is the model created by Grafstom failing to land? FIFA is running a dynamic pricing model for the 2025 CWC. In essence, the cost of tickets is dictated by demand: the more popular a fixture, the more it costs to attend. Real Madrid games, for instance, are holding up. None of their fixtures are cheaper than $132. Boca Juniors look like drawing crowds too. But sources spoken to by Adam said Miami were looking at an attendance of lower than 20,000 — 45,000 beneath capacity — for the first fixture. FIFA denied this but would not specify a figure itself. Tickets for that game are available for a lowest price of $55, far below the $230 being charged in January and $349 when the CWC draw was made before the turn of the year. There's a suspicion that plenty of CWC matches will play out in front of swathes of empty seats, an image FIFA wants to avoid. Advertisement Infantino has said previously he wasn't 'worried at all' about ticket sales, because the FIFA boss is a can-do sort. The world governing body insists fans from over 130 countries have purchased seats to date. Grafstrom told Felipe that the CWC should help football expand further in the States. It makes all the right noises, FIFA, but how much is it telling itself what it wants to hear? Sir Dave Brailsford is widely known as Mr Marginal Gains. In the days when he ran Team Sky, before trouble enveloped them, the cycling outfit were the Tour de France's tour de force. The 61-year-old is a key figure at INEOS, Manchester United's minority shareholder, so it stood to reason that when INEOS took a stake in United in 2023, Brailsford would bring his competitive mind to Old Trafford. He did — but yesterday it emerged that he's stepping back again. In INEOS' 18 months, United haven't made marginal gains. They haven't made large gains either. Brailsford has been in the thick of everything that's gone on — a period of on-field regression and deep financial cuts — and his return to the role of INEOS' director of sport can be taken as an admission that his input hasn't worked. At all. In another shuffle, Jason Wilcox is being promoted by United from technical director to director of football. It's a fresh rearrangement of the deckchairs, but Wilcox has a part to play. Not so Brailsford, who won't be roundly missed. You know it's the off season when professional footballers are participating in an on-field drag race with a Formula One car. That was the scene at Elland Road, where three members of Leeds United's squad tried (and predictably failed) to outpace Red Bull's RB7 model. Footnote: it didn't collide with any of them. Advertisement The purpose of the stunt? No idea, beyond a bit of fun, and the ground staff must have been thrilled. But in a serious sense, it's an example of how intertwined Red Bull is becoming with Leeds, its first equity investment in the English game. The purchase of club shares by Red Bull last year was going to be scrutinised, because of its contentious ownership history elsewhere in the world. But far from keeping its head down in Leeds, the energy drink giant — a minority partner — has its branding on the club's kit and its 2011 F1 car on their pitch. There's no missing the collaboration. Leeds' chairman, Paraag Marathe, said at the outset that a majority sale to Red Bull was not on the table. Perhaps that holds true. But I'm constantly fascinated to see if and how its interest evolves, in a league it is yet to crack. (Selected games, times ET/UK) UEFA Nations League semi-final: Spain vs France, 3pm/8pm — Fox Sports, Fubo/Amazon Prime. CONMEBOL World Cup qualifiers: Ecuador vs Brazil, 7pm/12am — Fanatiz PPV/Premier Sports; Paraguay vs Uruguay, 7pm/12pm — Fanatiz PPV (U.S. only); Chile vs Argentina, 9pm/2am — Fanatiz PPV (U.S. only). Virtually nobody on England's side of the Irish Sea would have registered the quiet, five-figure trade between Liverpool and Ringmahon Rangers in 2015. It moved a teenage Caoimhin Kelleher from Ireland to Anfield, long before the goalkeeper's name meant anything to the wider world. Ringmahon's secretary, Sean Fitzgerald, had the presence of mind to sweeten the deal with a 20 per cent sell-on clause. A decade on, and as a knock-on effect of Kelleher's £12.5m transfer from Liverpool to Brentford on Tuesday, it's about to pay out in the grassroots club's favour. The precise amount is yet to be calculated — but Fitzgerald isn't far wrong when he says the windfall should protect Ringmahon for 100 years. Safe hands all round.
